| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Department of Medicine (Q.L., Y.A.L., R.J.G.H.) and Department of Biochemistry, Microbiology and Immunology (Y.A.L., R.J.G.H.), University of Ottawa, and the Ottawa Health Research Institute (Q.L., A.S., J.C., Y.A.L., R.J.G.H.), Ottawa, Ontario, Canada K1Y 4E9
Address all correspondence and requests for reprints to: Robert J. G. Haché or Qiao Li, The Ottawa Health Research Institute, 725 Parkdale Avenue, Ottawa, Ontario, Canada, K1Y 4E9. E-mail: rhache@ohri.ca or qli{at}ohri.ca.
The effects of acetylation on gene expression are complex, with changes in chromatin accessibility intermingled with direct effects on transcriptional regulators. For the nuclear receptors, both positive and negative effects of acetylation on specific gene transcription have been observed. We report that p300 and steroid receptor coactivator 1 interact transiently with the glucocorticoid receptor and that the acetyltransferase activity of p300 makes an important contribution to glucocorticoid receptor-mediated transcription. Treatment of cells with the deacetylase inhibitor, sodium butyrate, inhibited steroid-induced transcription and altered the transient association of glucocorticoid receptor with p300 and steroid receptor coactivator 1. Additionally, sustained sodium butyrate treatment induced the degradation of p300 through the 26S proteasome pathway. Treatment with the proteasome inhibitor MG132 restored both the level of p300 protein and the transcriptional response to steroid over 20 h of treatment. These results reveal new levels for the regulatory control of gene expression by acetylation and suggest feedback control on p300 activity.
NURSA Molecule Pages Link:
This article has been cited by other articles:
 |
|
 |
|
  G.-d. Li, J.-x. Fang, H.-z. Chen, J. Luo, Z.-h. Zheng, Y.-m. Shen, and Q. Wu Negative regulation of transcription coactivator p300 by orphan receptor TR3 Nucleic Acids Res., December 18, 2007; 35(21): 7348 - 7359. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Yang, W. Wei, M. Menconi, and P.-O. Hasselgren Dexamethasone-induced protein degradation in cultured myotubes is p300/HAT dependent Am J Physiol Regulatory Integrative Comp Physiol, January 1, 2007; 292(1): R337 - R334. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. H Lee, J. L Volinic, C. Banz, K.-M. Yao, and M. K Thomas Interactions with p300 enhance transcriptional activation by the PDZ-domain coactivator Bridge-1 J. Endocrinol., November 1, 2005; 187(2): 283 - 292. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Chen, J. R. St-Germain, and Q. Li B56 Regulatory Subunit of Protein Phosphatase 2A Mediates Valproic Acid-Induced p300 Degradation Mol. Cell. Biol., January 15, 2005; 25(2): 525 - 532. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. L. Smith and B. W. O'Malley Coregulator Function: A Key to Understanding Tissue Specificity of Selective Receptor Modulators Endocr. Rev., February 1, 2004; 25(1): 45 - 71. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Brouillard and C. E. Cremisi Concomitant Increase of Histone Acetyltransferase Activity and Degradation of p300 during Retinoic Acid-induced Differentiation of F9 Cells J. Biol. Chem., October 10, 2003; 278(41): 39509 - 39516. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. De Bosscher, W. Vanden Berghe, and G. Haegeman The Interplay between the Glucocorticoid Receptor and Nuclear Factor-{kappa}B or Activator Protein-1: Molecular Mechanisms for Gene Repression Endocr. Rev., August 1, 2003; 24(4): 488 - 522. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |
